Gilead price target lowered to $80 from $81 at Barclays

Barclays analyst Carter Gould lowered the firm’s price target on Gilead to $80 from $81 and keeps an Equal Weight rating on the shares. The magrolimab failure is not surprising, but still represents another setback for Gilead’s oncology build-out, the analyst tells investors in a research note.